Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Chalasani

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Gastrointestinal Endoscopy|March 7, 2001
Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitisA R Baluyut, S Sherman, G A Lehman, et al.
Alimentary Pharmacology & Therapeutics|November 29, 2014
NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levelsK E Corey, R Vuppalanchi, L A Wilson, et al.
Digestive Diseases and Sciences|May 3, 2021
Patients with Autoimmune Hepatitis Report Lower Lifetime Coffee ConsumptionCraig Lammert, Sai N Chalasani, Kelsey Green, et al.
Hepatology (Baltimore, Md.)|December 4, 2001
Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shuntsN Chalasani, J C Gorski, N H Patel, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 12, 2021
Environmental risk factors are associated with autoimmune hepatitisCraig Lammert, Sai N Chalasani, Elizabeth J Atkinson, et al.
Alimentary Pharmacology & Therapeutics|July 20, 2007
Predictors of outcome in patients with unresectable hepatocellular carcinoma receiving transcatheter arterial chemoembolizationH Shen, D Agarwal, R Qi, et al.
British Journal of Clinical Pharmacology|April 2, 2005
Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or proteinA G Pinto, J Horlander, N Chalasani, et al.
Alimentary Pharmacology & Therapeutics|October 13, 2010
The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascitesV L Misra, R Vuppalanchi, D Jones, et al.
The American Journal of the Medical Sciences|November 11, 1999
Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantationJ C Horlander, N Boyle, R Manam, et al.
Alimentary Pharmacology & Therapeutics|January 16, 2018
Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitisB Hameed, N A Terrault, R M Gill, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Gastrointestinal Endoscopy|March 7, 2001
Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitisA R Baluyut, S Sherman, G A Lehman, et al.
Alimentary Pharmacology & Therapeutics|November 29, 2014
NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levelsK E Corey, R Vuppalanchi, L A Wilson, et al.
Digestive Diseases and Sciences|May 3, 2021
Patients with Autoimmune Hepatitis Report Lower Lifetime Coffee ConsumptionCraig Lammert, Sai N Chalasani, Kelsey Green, et al.
Hepatology (Baltimore, Md.)|December 4, 2001
Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shuntsN Chalasani, J C Gorski, N H Patel, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 12, 2021
Environmental risk factors are associated with autoimmune hepatitisCraig Lammert, Sai N Chalasani, Elizabeth J Atkinson, et al.
Alimentary Pharmacology & Therapeutics|July 20, 2007
Predictors of outcome in patients with unresectable hepatocellular carcinoma receiving transcatheter arterial chemoembolizationH Shen, D Agarwal, R Qi, et al.
British Journal of Clinical Pharmacology|April 2, 2005
Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or proteinA G Pinto, J Horlander, N Chalasani, et al.
Alimentary Pharmacology & Therapeutics|October 13, 2010
The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascitesV L Misra, R Vuppalanchi, D Jones, et al.
The American Journal of the Medical Sciences|November 11, 1999
Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantationJ C Horlander, N Boyle, R Manam, et al.
Alimentary Pharmacology & Therapeutics|January 16, 2018
Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitisB Hameed, N A Terrault, R M Gill, et al.
Pageof 5